Lapacent Tablet 250 mg contains Lapatinib, an oral targeted anticancer therapy used in the management of HER2-positive advanced or metastatic breast cancer. Lapatinib is a dual tyrosine kinase inhibitor that specifically targets receptors involved in tumor cell growth and survival. It is commonly prescribed in combination with other anticancer agents such as capecitabine or letrozole, depending on the clinical condition of the patient. Lapacent 250 mg is designed for long-term oral administration, offering convenience and sustained therapeutic control.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Targeted Cancer Therapy / Tyrosine Kinase Inhibitor

Pharmacology

Lapatinib is a reversible inhibitor of the intracellular tyrosine kinase domains of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). These receptors play a crucial role in cell proliferation, angiogenesis, and tumor progression.

By blocking phosphorylation and downstream signaling pathways such as PI3K/AKT and MAPK, Lapatinib suppresses tumor cell growth and induces apoptosis in HER2-overexpressing cancer cells. Unlike monoclonal antibodies, Lapatinib acts intracellularly, making it effective even in some tumors resistant to trastuzumab.

Pharmacokinetic properties include:

• Absorption: Oral, with peak plasma concentration reached within 3–6 hours

• Bioavailability: Increased with food intake

• Protein binding: Greater than 99%

• Metabolism: Primarily hepatic via CYP3A4 and CYP3A5

• Elimination half-life: Approximately 24 hours

• Excretion: Mainly through feces

Indications

Lapacent Tablet 250 mg is indicated for:

• HER2-positive metastatic breast cancer in combination with capecitabine in patients who have received prior therapy including anthracycline, taxane, and trastuzumab

• Hormone receptor-positive, HER2-positive metastatic breast cancer in postmenopausal women, in combination with letrozole

Dosage and Administration

• The usual recommended dose of Lapatinib is 1,000–1,250 mg once daily, depending on the treatment regimen

• Tablets should be taken once daily at the same time, either at least 1 hour before or 1 hour after meals

• Tablets must be swallowed whole with water and should not be crushed or chewed

• Treatment duration depends on disease progression and patient tolerance

Dose Adjustments:

• May be required in patients with hepatic impairment

• Temporary interruption or dose reduction may be necessary in case of severe adverse reactions

Contraindications

• Known hypersensitivity to Lapatinib or any component of the formulation

• Severe hepatic impairment unless clearly indicated and closely monitored

Side Effects

Commonly reported side effects include:

• Diarrhea, nausea, vomiting, and abdominal pain

• Rash, dry skin, and hand-foot syndrome

• Fatigue and headache

• Decreased appetite

• Elevation of liver enzymes

Serious but less common effects may include cardiotoxicity, interstitial lung disease, and severe hepatotoxicity.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Liver function tests should be monitored regularly

• Cardiac function assessment is recommended before and during treatment

• Use with caution when co-administered with strong CYP3A4 inhibitors or inducers

• Adequate contraception is advised during treatment

Pregnancy and Lactation

• Pregnancy Category D: Lapatinib may cause fetal harm and should not be used during pregnancy

• Breastfeeding is not recommended during treatment due to potential risk to the infant

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.

Mode of Action

Lapacent 250 mg works by inhibiting EGFR and HER2 tyrosine kinases, thereby blocking cancer cell signaling pathways responsible for uncontrolled growth and survival. This targeted mechanism helps slow disease progression and improve treatment outcomes in HER2-positive breast cancer.